AINDEX
Markets

Acadia Pharmaceuticals Inc. (ACAD)

ACADNASDAQ-GSBiotechnology: Pharmaceutical Preparations

$18.67

+0.1990 (+1.08%) today

At the close, Nov 16, 4:00 PM ET. Pre-market $18.49 -0.96%

+2.72% 1D
Market cap
$3.20bn
P/E
27.9
EPS, last 4 quarters
$0.6700
Dividend yield
–
Day range
–
52-week range
$15.86 to $30.96
Average volume
–
Previous close
$18.47

Analysts

14 covering

Buy10 buy, 4 hold, 0 sell

Targets a year out average $31.43, +68.3% from here

$23.00now $18.67$38.00

Earnings

next estimate $0.2800

Next report

Dec 2025

+33.3%

Mar 2026

-50.0%

Jun 2026

+200.0%

Sep 2026

+63.2%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$283.99m$268.06m$307.96m$342.29m
Gross profit$257.76m$243.27m$279.64m$307.20m
Operating income$17.39m-$4.62m$37.84m$71.72m
Net income$273.57m$3.64m$31.50m$53.52m

Last four quarters: revenue $1.20bn, margin 30.1%, free cash flow $81.99m

News

8 latest

The company

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we're here to be their difference.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
North America
Website
acadia.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.